Navigation Links
Cancer Antibodies: Drug Target Atlas and Competitive Outlook
Date:11/15/2012

e Peptidase Activity Targets 2886.2.42 Structural Constituent of Cytoskeleton Targets 2916.2.43 Structural Molecule Activity Targets 2936.2.44 T Cell Receptor Activity Targets 2946.2.45 Transcription Factor Activity Targets 2966.2.46 Transcription Regulator Activity Targets 3016.2.47 Translation Regulator Activity Targets 3046.2.48 Transmembrane Receptor Activity Targets 3056.2.49 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 3146.2.50 Transporter Activity Targets 3486.2.51 Other Targets 3526.3 Mutation Profiles of Antibody Drug Targets in Oncology 3566.3.1 Targets of Antibody Drugs in Cancer Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 3566.4 Antibody Therapeutics is Stimulated by Available Structure Data on Targets 3646.5 Target-Target Interactions among Identified Targets of Antibody Drugs in Cancer 3686.6 Protein Expression Levels of Identified Targets of Antibody Drugs in Cancer 3726.7 The Drug-Target Competitive Landscape 3756.8 Pathway Assessment of Antibody Drugs in Cancer 3816.8.1 Tools for Analysis of Cancer Pathways 3826.8.2 Pathway Assessment 3837 Emerging Drug Candidates to Established Ones: Drug Target Strategies of Antibody Drugs in Cancer by their Highest Stage of Development 4237.1 Pre-registrered and Marketed: New and Unique Drug Target Strategies of Antibody Drugs in Cancer 4267.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Antibody Drugs in Cancer 4287.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Antibody Drugs in Cancer 4307.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Antibody Drugs in Cancer 4357.5 Preclinical Development: New and Unique Drug Target Strategies of Antibody Drugs in Cancer 4427.6 Drug Target Strategies of Suspended or Terminated Antibody Drugs in Cancer 4517.7 Target Strategy Development Profiles of Antibody Drugs in Cancer 4567.7.1 Marketed 4627.7.2 Phase III 4837.7.3 Phase II 4987.7.4
'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
2. Virobays Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
3. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
4. NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
5. Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer
6. Masaryk Memorial Cancer Institute Reduces Losses and Administrative Overhead With Ekahau RTLS
7. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
8. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
9. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
10. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
11. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... , ... Inc. Magazine released its annual list of the 5,000 fastest-growing privately ... for the three years through 2014. Being named to the Inc. 5000 list designates ... country. , “We are thrilled to make the Inc. 5000 list for 2015,” ...
(Date:8/26/2015)... 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended June 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... to our Oral Amp B program, rapidly advancing ... Andrew Rae , President & CEO of ...
(Date:8/26/2015)... 26, 2015 Intrexon Corporation (NYSE: XON ... closing of its previously announced public offering of common ... of their option to purchase an additional 731,707 shares ... $41.00 per share.  The exercise of the underwriters, option ... sold by Intrexon to 5,609,756 shares and increased the ...
(Date:8/26/2015)... ... , ... PRC Clinical, a Clinical Trial Management Expert CRO, will ... southern California. The Clinical Trial Management Expert CRO seeks to introduce more California-based sponsors ... , Stem Cell Meeting on the Mesa on October 7-9 ...
Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... (OTC Bulletin Board: GNTA) announced today that the ... accredited,investors to place Senior Secured Convertible Notes due ... gross proceeds before fees and expenses. The,closing of ... to take place on or,about June 6, 2008, ...
... Mich., June 5 Compendia Bioscience today,announced ... agreement with,GlaxoSmithKline (NYSE: GSK ) for ... flagship product, Oncomine.,Oncomine Enterprise Edition builds upon ... by integrating the ability to securely,view proprietary ...
... SAN FRANCISCO, Calif., June 5 Exelixis,Inc. (Nasdaq: ... into an,agreement with Deerfield Management, a leading healthcare investment,organization ... $150.0 million in financing through a flexible credit facility. ... next 18 months at Exelixis,discretion. Exelixis is under no ...
Cached Biology Technology:Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs 2Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs 3Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs 4GlaxoSmithKline Signs Licensing Agreement With Compendia Bioscience 2Exelixis Receives $150 Million Funding Commitment From Deerfield Management 2Exelixis Receives $150 Million Funding Commitment From Deerfield Management 3Exelixis Receives $150 Million Funding Commitment From Deerfield Management 4Exelixis Receives $150 Million Funding Commitment From Deerfield Management 5
(Date:8/20/2015)... , Aug. 20, 2015   Sensory, ... on improving the user experience and security of ... technologies, today announced that its TrulySecure™ ... authentication software to be FIDO Certified™. ... for compliance with the FIDO UAF (Universal Authentication ...
(Date:8/18/2015)... , Aug. 17, 2015 Research ... addition of the "Global Biometric Authentication & ... - Estimation & Forecast, 2015-2020" report to ... authentication and identification systems market is expected to ... 2015 to 2020 and generate over $25 billion ...
(Date:8/12/2015)... Aug. 12, 2015  New research unveiled at ... Android phones to steal users, fingerprints. Information released ... of fingerprint scanners on mobile devices, making the ... secure biometrics on mobile devices, HYPR Corp. recently ... convenient authentication systems with strong cryptographic security. More ...
Breaking Biology News(10 mins):TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3
... Voelker, PhD, professor of medicine at National Jewish ... for various lipids and related compounds that can ... those caused by influenza and respiratory syncytial virus ... has published several scientific papers describing a naturally ...
... is available in Spanish . Professor ... University of the Basque Country and Director of the Biophysics ... award. This award is the most important in the world ... Biophysics has issued this award, but this year for the ...
... that certain Australian native flowers have shifted away from using ... red hues favoured by birds. In a study published ... RMIT University have shown for the first time that Australian ... signatures that are best discriminated by those birds. Dr ...
Cached Biology News:Felix Goñi, Avanti award for best European research in lipids 2For birds, red means 'go' 2
... , 25 g Blocking Reagent , 2 x ... T7 Elution Buffer , 0.2 ml BL21 glycerol stock ... ml BLT5615 glycerol stock , 1010 pfu T7Select Positive ... , 50 l S-protein HRP Conjugate , 2 ...
... WesternBreeze Immunodetection Kits are designed ... immobilized on nitrocellulose or PVDF membranes. ... (except membranes and primary antibodies), the ... both optimizing your protocol and getting ...
... Mouse Monoclonal to L1 Cell Adhesion Molecule ... is located in Xq28, is involved in ... the aqueduct of Sylvius); 2) MASA (mental ... 3) SPG1 (spastic paraplegia). Immunogen: ...
Immunogen: C terminus [VQLKRSKNDSKPYC] of cardiac elav-type RNA-binding protein (ETR-3) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: